Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02601014
Title Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

prostate adenocarcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.